

R H I N O M E D

Results of the RNO Share Purchase Plan

29 January 2024: Melbourne, Australia.

Rhinomed Limited (ASX: RNO, OTCQB:RHNMF) (**RNO** or the **Company**) is pleased to announce the results of the Company's Share Purchase Plan (**SPP**) which closed at 5.00pm (AEDT) on Thursday, 25 January 2024.

The Company has received applications totalling A\$42,206 from eligible shareholders to subscribe for 1,055,165 new shares at A\$0.04 per share.

The Company will allot the shares and dispatch holding statements in relation to the SPP on Friday, 2 February 2024.

This report has been authorised for release to the market by the Company Secretary.

Company	Investor and Media Relations
Michael Johnson, CEO & Director +61 (0) 3 8416 0900 mjohnson@rhinomed.global Follow us on Twitter @rhinomedceo	Rudi Michelson Monsoon Communications +61(0) 411 402 737 rudim@monsoon.com.au

About Rhinomed Limited (ASX: RNO, OTCQB:RHNMF)

Rhinomed Limited is a Melbourne, Australia based ASX listed nasal and airway technology company that has developed an innovative nasal technology platform that can improve air flow and provide both drug delivery and diagnostic capabilities.